BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALTA3263 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALTA3263\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06835569-2343@assetmemo.bio
DTSTAMP:20261121T004532Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:ALTA3263: Phase 1 readout est. (NCT06835569)
DESCRIPTION:ALTA3263\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tum
 ors With KRAS Mutations\nEstimated primary completion: May 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/alta3263#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06835569
URL:https://assetmemo.bio/drug/alta3263#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
